Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
2(12%)
Results Posted
33%(3 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_1
1
6%
Ph phase_4
1
6%
Ph not_applicable
4
24%
Ph phase_3
2
12%
Ph early_phase_1
5
29%
Ph phase_2
4
24%

Phase Distribution

6

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution17 total trials
Early Phase 1First-in-human
5(29.4%)
Phase 1Safety & dosage
1(5.9%)
Phase 2Efficacy & side effects
4(23.5%)
Phase 3Large-scale testing
2(11.8%)
Phase 4Post-market surveillance
1(5.9%)
N/ANon-phased studies
4(23.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.8%

9 of 11 finished

Non-Completion Rate

18.2%

2 ended early

Currently Active

2

trials recruiting

Total Trials

17

all time

Status Distribution
Active(3)
Completed(9)
Terminated(2)
Other(3)

Detailed Status

Completed9
unknown3
Active, not recruiting2
Withdrawn1
Terminated1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
17
Active
2
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 15 (29.4%)
Phase 11 (5.9%)
Phase 24 (23.5%)
Phase 32 (11.8%)
Phase 41 (5.9%)
N/A4 (23.5%)

Trials by Status

active_not_recruiting212%
unknown318%
withdrawn16%
terminated16%
completed953%
not_yet_recruiting16%

Recent Activity

2 active trials
Showing 5 of 17
terminatedphase_2

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT05498220
completedearly_phase_1

Hyaluronidase Via LADD Scleroderma-induced Microstomia

NCT05995626
active_not_recruitingphase_2

Peripheral Modulation of Muscle Stiffness and Spasticity

NCT03306615
completednot_applicable

Effect of Adding Hyaluronidase to Bupivacaine in Transversus Abdominis Plane Block for Cesarean Section

NCT05671172
not_yet_recruitingearly_phase_1

Effect of Hyaluronidase in Different Doses Added to Bupivacaine on TAB Block Quality During CS

NCT06839391
View all 17 trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT05498220Phase 2

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Terminated
NCT05995626Early Phase 1

Hyaluronidase Via LADD Scleroderma-induced Microstomia

Completed
NCT03306615Phase 2

Peripheral Modulation of Muscle Stiffness and Spasticity

Active Not Recruiting
NCT05671172Not Applicable

Effect of Adding Hyaluronidase to Bupivacaine in Transversus Abdominis Plane Block for Cesarean Section

Completed
NCT06839391Early Phase 1

Effect of Hyaluronidase in Different Doses Added to Bupivacaine on TAB Block Quality During CS

Not Yet Recruiting
NCT01722916Early Phase 1

Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase

Active Not Recruiting
NCT06604546Phase 3

Hyaluronidase Assisted Subcutaneous Infusion

Completed
NCT01945099Early Phase 1

Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy

Completed
NCT05083663Phase 2

Effectiveness of Adding Hyaluronidase to Bupivacaine in Ultrasound Guided Supraclavicular Brachial Plexus Block

Unknown
NCT03660020Not Applicable

Ultrasound Guided Erector Spinae Plane Block in Breast Surgery

Unknown
NCT02199028Phase 1

Hyaluronidase Effect on Infusion Set Life

Completed
NCT03411330Early Phase 1

Safety and Efficacy of Addition of Hyaluronidase to Lidocaine and Bupivacaine in Scalp Nerves Block in Elective Craniotomy Operations, Comparative Study

Completed
NCT03266406Not Applicable

Effect of Hyaluronidase on Intraocular Pressure

Unknown
NCT01689363Phase 2

Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)

Completed
NCT00000493Phase 3

Multicenter Investigation of Limitation of Infarct Size (MILIS)

Completed
NCT02059694Not Applicable

Use of Recombinant Hyaluronidase Human is Effective for the Use of Local Blocks for Eyelid's Surgery

Withdrawn
NCT01719978Phase 4

Hemodynamic and Electrocardiographic Effects of Hyaluronidase Associated With Local Anaesthetics

Completed

All 17 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
17